The MelaFind handheld multispectral dermoscope assists in the evaluation of pigmented lesions.
How useful are computer vision tools in the diagnosis of pigmented lesions (PLs)? Investigators conducted a prospective, multicenter, blinded trial of MelaFind, a multispectral imaging tool, for identifying which PLs should be biopsied to rule out melanoma. Patients with at least one suspicious lesion targeted for biopsy were included. Melanomas (invasive and in situ) and borderline lesions, such as high-grade dysplastic nevi (HGDN), atypical melanocytic proliferation (AMP), and atypical melanocytic hyperplasia (AMH), were evaluated; PLs with a prebiopsy melanoma diagnosis were excluded.
Dermatopathology was used as the reference standard for evaluating the diagnostic performances of MelaFind and of clinicians. Of 1632 eligible and evaluable…
Reviewing Author
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)
DisclosuresConsultant / advisory board Lubax; WorldCare Clinical
EquityLubax
Grant / Research support NIH; Department of Defense; American Skin Association; Piramal
Editorial boardsBritish Journal of Dermatology; Journal of the American Academy of Dermatology; Journal of Investigative Dermatology
Leadership positions in professional societies American Academy of Dermatology (Chair, Skin Cancer and Melanoma Committee); American Board of Dermatology (Director)